Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders

Launched by MAYO CLINIC · Mar 20, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a medication called ravulizumab to see if it can help women who are experiencing severe preeclampsia or HELLP syndrome during pregnancy. Preeclampsia is a serious condition that can happen after the 20th week of pregnancy and can affect both the mother and the baby. The researchers are looking for women who are between 6 and 34 weeks pregnant and have been diagnosed with these conditions to participate in the study.

To be eligible, women must be experiencing severe preeclampsia or HELLP features and be less than 34 weeks pregnant. However, there are some criteria that would exclude someone from the trial, such as having certain serious health issues or complications with the baby. Participants in the trial will receive the study medication and be monitored closely by healthcare professionals. This research aims to find out if ravulizumab can provide a safer option for managing these severe pregnancy complications.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Individuals with \< 34 0/7 weeks of gestation.
• • Individuals with severe preeclampsia or HELLP features.
• Exclusion Criteria:
• • Pregnant female patients presenting with disseminated intravascular coagulopathy (DIC).
• • Individuals with non-reassuring fetal status requiring delivery, non-viable fetuses, previable pregnancy (\<23 0/7 weeks gestation), stroke, in utero fetal demise, known atypical hemolytic uremic syndrome, familial or acquired thrombocytopenia purpura, paroxysmal nocturnal hemoglobinuria, allergy to Ravulizumab, inability or unwillingness to sign informed consent.